GRI Bio Stock (NASDAQ:GRI)

Revenue Financials Chart

Previous Close

$5.64

52W Range

$5.12 - $333.20

50D Avg

$23.30

200D Avg

$40.29

Market Cap

$498.57K

Avg Vol (3M)

$88.84K

Beta

-1.25

Div Yield

GRI Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 24, 2023

Website

GRI Performance

GRI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-8.23M	$-11.39M	$-2.24M
Net Income	$-8.21M	$-13.04M	$-3.22M
EBITDA	$-8.23M	$-10.90M	$-2.51M
Basic EPS	$-55.21	$-6.24K	$-165.35K
Diluted EPS	$-55.21	$-6.24K	$-165.35K

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
JAGX	Jaguar Health, Inc.
SILO	Silo Pharma, Inc.
INM	InMed Pharmaceuticals Inc.
ABP	Abpro Corporation
CNSP	CNS Pharmaceuticals, Inc.
SXTP	60 Degrees Pharmaceuticals, Inc.
GNPX	Genprex, Inc.